A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

A research team from the University of Osaka, in collaboration with the Massachusetts Institute of Technology, has uncovered ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

The company scans entire proteins with CRISPR to find functional vulnerabilities, then hunts for molecules that exploit them ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

A CRISPR system detects rare cancer mutations in blood with single-nucleotide precision, outperforming ddPCR through engineered RNA guides and isothermal amplification. (Nanowerk Spotlight) Hidden ...

A study harnessing a successful treatment for lymphoma and applying it to other cancers promises a breakthrough in how to attack a range of tumours using the body’s own immune system.

“While recent single-cell multiomics studies and CRISPR screens in murine NK cells have expanded our understanding, actionable genomic targets in primary human NK cells have remained largely ...

California biotech company Cellipont has opened a new 76,000 square foot cell therapy headquarters in The Woodlands' booming ...